Biora Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.
| Earnings Date | 11/16/2026 |
As of September 30, 2024, Biora Therapeutics, Inc. has 3.68M shares outstanding.
| Shares Outstanding | 3.68M |
As of September 30, 2024, Biora Therapeutics, Inc. maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -37.18, indicating conservative leverage, while an interest coverage ratio of -8.25 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.05 |
| Quick Ratio | 0.03 |
| Debt / Equity | -37.18 |
| Debt / EBITDA | -0.66 |
| Interest Coverage | -8.25 |
These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -128.19, reflecting losses generated across the asset base. The company generates approximately 15,379.31 in revenue per employee across its workforce of 58.00, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -128.19 |
| Revenue Per Employee | 15,379.31 |
| Employee Count | 58.00 |
Over the twelve months ended September 30, 2024, Biora Therapeutics, Inc. recorded an income tax benefit of -158,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -35.73M and -31.54M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -158,000.00 |
As of the close on November 10, 2026, Biora Therapeutics, Inc.'s stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.06.
| 200-Day Moving Average | 0.06 |
Over the twelve months ended September 30, 2024, Biora Therapeutics, Inc. generated 892,000.00 in revenue and converted that into -31.54M in net income, yielding earnings per share of -9.71. EBITDA reached -60.43M, while operating income came in at -60.87M.
| Revenue | 892,000.00 |
| Operating Income | -60.87M |
| Pretax Income | -35.73M |
| Net Income | -31.54M |
| EBITDA | -60.43M |
| EBIT | -60.87M |
| Earnings Per Share (EPS) | -9.71 |
As of September 30, 2024, Biora Therapeutics, Inc. holds 3.20M in cash and equivalents against 39.65M in total debt, resulting in a net debt position of 35.40M. Total book value stands at -106.63M, with working capital of -114.56M providing operational flexibility.
| Cash & Cash Equivalents | 3.20M |
| Total Debt | 39.65M |
| Net Debt | 35.40M |
| Equity (Book Value) | -106.63M |
| Book Value Per Share | -28.99 |
| Working Capital | -114.56M |
Biora Therapeutics, Inc. produced -45.92M in operating cash flow over the twelve months ended September 30, 2024. After subtracting -280,000.00 in capital expenditures, free cash flow totaled -46.20M - equivalent to -17.11 per share.
| Operating Cash Flow | -45.92M |
| Capital Expenditures | -280,000.00 |
| Free Cash Flow | -46.20M |
| FCF Per Share | -17.11 |
These figures cover the twelve months ended September 30, 2024. The operating margin of -6,824.33 and net profit margin of -3,535.76 provide insight into operational efficiency.
| Operating Margin | -6,824.33 |
| Pretax Margin | -4,005.83 |
| Profit Margin | -3,535.76 |
| EBITDA Margin | -6,774.66 |
Biora Therapeutics, Inc.'s most recent stock split took place on October 18, 2024 with a 10:1 split ratio.
| Last Split Date | 10/18/2024 |
| Split Ratio | 10:1 |